Related Experiment Video
Updated: Oct 22, 2025
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer
Muzamil Y Want1, Ellen Karasik2, Bryan Gillard2
1Department of Immunology, Division of Translational Immuno Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Abstract:
Immunotherapy initially demonstrated promising results in prostate cancer (PCa), but the modest or negative results of many recent trials highlight the need to overcome the poor immunogenicity of this cancer. The design of effective therapies for PCa is challenged by the limited understanding of the interface between PCa cells and the immune system in mediating therapeutic resistance. Prompted by our recent observations that elevated WHSC1, a histone methyltransferase known to promote progression of numerous cancers, can silence antigen processing and presentation in PCa, we performed a single-cell analysis of the intratumoral immune dynamics following in vivo pharmacological inhibition of WHSC1 in mice grafted with TRAMP C2 cells. We observed an increase in cytotoxic T and NK cells accumulation and effector function, accompanied by a parallel remodeling of the myeloid compartment, as well as abundant shifts in key ligand-receptor signaling pathways highlighting changes in cell-to-cell communication driven by WHSC1 inhibition. This comprehensive profiling of both immune and molecular changes during the course of WHSC1 blockade deepens our fundamental understanding of how anti-tumor immune responses develop and can be enhanced therapeutically for PCa.
Insights
Targeting WHSC1 (histone methyltransferase) enhances anti-tumor immunity in prostate cancer (PCa). This approach boosts cytotoxic T and NK cell activity, offering a new therapeutic strategy for PCa immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Prostate cancer (PCa) exhibits poor immunogenicity, limiting the efficacy of immunotherapy.
- Understanding the interaction between PCa cells and the immune system is crucial for overcoming therapeutic resistance.
Purpose of the Study:
- To investigate the role of WHSC1 (histone methyltransferase) in regulating anti-tumor immunity in PCa.
- To analyze the effects of WHSC1 inhibition on the tumor microenvironment and immune cell dynamics.
Main Methods:
- Single-cell analysis of intratumoral immune responses in mice with TRAMP C2 prostate tumors.
- Pharmacological inhibition of WHSC1 in vivo.
- Assessment of immune cell accumulation, effector function, myeloid compartment remodeling, and ligand-receptor signaling pathways.
Main Results:
- WHSC1 inhibition led to increased accumulation and enhanced effector function of cytotoxic T and NK cells.
- Significant remodeling of the myeloid compartment was observed.
- Key ligand-receptor signaling pathways were altered, indicating changes in cell-to-cell communication.
Conclusions:
- Pharmacological inhibition of WHSC1 effectively enhances anti-tumor immune responses in prostate cancer.
- WHSC1 blockade modulates both immune cell populations and molecular signaling within the tumor microenvironment.
- This study provides a deeper understanding of immune enhancement strategies for PCa therapy.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:20The JAK-STAT Signaling Pathway